Baidu
map

一天公布两个合作公告,IBM沃森又有大动作

2017-02-24 动脉网 动脉网

2月24日凌晨0点21分,在大家即将进入睡梦的时候,IBM中国官方微信发布了两条合作公告,第一是与CNYCC合作改善社区居民健康水平,另一个是与Atrius Health共同开发一个基于云的服务来改善医患体验。两个组织都是非盈利组织,沃森意欲何为呢?一、CNYCCCNYCC即Central NewYork Care Collaborative,是一个非营利组织,它将纽约州中部6县的2,000多

2月24日凌晨0点21分,在大家即将进入睡梦的时候,IBM中国官方微信发布了两条合作公告,第一是与CNYCC合作改善社区居民健康水平,另一个是与Atrius Health共同开发一个基于云的服务来改善医患体验。两个组织都是非盈利组织,沃森意欲何为呢?

一、CNYCC

CNYCC即Central NewYork Care Collaborative,是一个非营利组织,它将纽约州中部6县的2,000多家医疗和社区服务提供商联系起来。

作为一家实施纽约州Delivery System Reform Incentive Payment(DSRIP)计划的领导机构,CNYCC与170多个组织合作来协调护理服务,提高该地区20多万Medicaid受益人和无保险患者获得医疗服务的能力。CNYCC的另一项任务是,帮助医疗安全网提供商转型到基于价值的护理服务支付模式。

这次Watson Health与CNYCC合作就是要创建一个认知人口健康平台,用于连接纽约州中部6县的2,000多家医疗和社区服务提供商。该平台的成立宗旨在于帮助改善区域内居民的健康状况。

在项目实施期间将减少25%的非必要急诊就医和再入院次数,从而降低Medicaid(美国联邦医疗补助计划)体系的成本。该人口健康平台将且在Watson Health Cloud上运行。

据麦肯锡数据显示,医疗行业数据中存在大量洞察亟待开发,其年均价值预计约为3000亿美元。患者数据常常位于多个孤岛上,阻碍医生了解影响患者护理质量的健康问题和潜在风险因素。例如,一位内分泌医师可能不知道她的糖尿病患者同时患有抑郁症,这会带来不依从性的严重医疗风险。

对于CNYCC的人口健康管理(PHM)系统,IBM Watson Health将集成多种治疗场景——初诊治疗、急性后期护理、行为健康、社区和急性护理——以及超过75个电子健康记录系统、健康信息交流平台以及其他数据来源。

CNYCC的人口健康管理(PHM)系统将聚合多样化数据,形成对患者病况的整体把握,包含临床病例、社会决定因素和行为健康。临床医生可通过该平台访问患者信息,选择联系患者以提醒从速办理寻医就诊、护理管理;例如发送一个让患者领取药方的私下提醒。

IBM Watson Health Value-Based Care副总裁兼首席健康信息官、医学博士、FACP成员,AnilJain先生说:“Central NewYork正在引领一场全美国的医疗演进,将走向高效可扩展、以患者为中心的人口健康管理和基于价值的医疗。关键在于找出高风险个人,使用Watson助力的工具和服务,帮助医疗提供商联络患者,从而改善患者的健康状况。随着医疗行业从“按服务收费”模式转向基于价值的系统,护理服务提供商需要一体化的解决方案,以获得病患群体中每位患者的全面透视。

Watson Care Manager将护理管理最佳实践与自动执行的工作流相结合,使护理经理有能力创建个性化护理计划,兼顾各种健康相关因素,并让个人联合参与提高健康水平。该系统将Watson的认知计算功能与IBM在人口健康管理和社会项目管理方面的现有专家经验相结合。

除了揭示特定患者的信息,它还能运行相似性分析,利用Watson Health Cloud中更广泛的健康数据,帮助临床医生找出类似患者的潜在风险因素。重要的是,Watson Health的人口健康平台提供了无缝的患者互动功能,打造了从患者洞察到医患互动、再到开展治疗的完整医疗流程。

二、Atrius Health

Atrius Health,也是一家非营利医疗领先组织,为马萨诸塞州中东部的675,000多位成人和儿科患者提供了一个有效的互联护理系统。

Atrius Health拥有30个医学实践机构,50多个专科和875位医生,他们与该组织的VNACare附属机构的家庭健康和救济院服务人员协同工作,并与医院合伙人、社区专家和专业护理机构紧密合作。Atrius Health向其服务的每位患者提供高质量、以患者为中心、协同式的护理。

与Atrius Health的协议,将开发一个基于云的服务来改善医患体验。通过提供个人健康多种影响因素(包括社会决定因素)的整体视图,Watson Cognitive Insights可支持医生与患者共同决策。

依据Health Affairs发表的文章,共同决策(医生及其患者根据最佳临床证据一起做出医疗决策)与患者、临床医生和医疗保健体系的诸多益处密切相关。例如提高病患认知、减少治疗过程中的焦虑、改善健康结果、减少无根据的护理和成本变化,以及提供更加符合患者利益的护理。尽管存在诸多好处,许多医生仍然表明很难将共同决策技术整合到他们与患者的直接互动中。

要解决这些挑战,可以设计新的解决方案,将电子健康记录系统整合到医生工作流程中。这种解决方案可以总结患者健康状态的关键认知洞察,收集与该患者类似的去标识化的人群,描述这些人在不同治疗选择下的健康结果。

IBM Watson Health副总裁兼首席健康转型官、医学博士Paul Tang先生说:“Watson的自然语言处理功能可读取和理解电子健康记录中的临床笔记。如果与其他高级技术相结合,它还可提取有关个人健康的关键洞察并应对干预。拥有了个人的全面信息和类似患者治疗成果的洞察,医生就能更有把握地制定个性化的病人护理计划。”

Atrius Health的总裁兼CEO、医学博士Steve Strongwater说:“Atrius Health致力于增加临床医生和医务职员在医学治疗中的积极情绪。Atrius Health借助与IBMW atson Health的合作良机,帮助临床医生更有效地利用每日患者护理中生成的海量数字化信息。Watson Cognitive Insights的独特能力将帮助我们的初级治疗医生提高效力和效率。而且,我们预计这次合作将帮助我们更准确地识别、弥合护理缺口,从而改善非固定临床护理的质量和安全。”

通过与IBM Watson Health合作开发这项新解决方案,Atrius Health旨在确保在医疗点应用强大的分析来支持实际的医患对话。

这又是Watson人工智能系统作为工具,在医疗的新应用,我们期待人工智能给我们更多地改善。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1489933, encodeId=ea0f148993307, content=<a href='/topic/show?id=f91c93134e' target=_blank style='color:#2F92EE;'>#IBM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9313, encryptionId=f91c93134e, topicName=IBM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0288649873, createdName=tulenzi, createdTime=Sun Feb 26 05:24:00 CST 2017, time=2017-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621480, encodeId=1744162148088, content=<a href='/topic/show?id=82519314a5' target=_blank style='color:#2F92EE;'>#IBM沃森#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9314, encryptionId=82519314a5, topicName=IBM沃森)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d0520274481, createdName=yese, createdTime=Sun Feb 26 05:24:00 CST 2017, time=2017-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177858, encodeId=6ba81e78582a, content=更多的合作与思考, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sat Feb 25 13:44:38 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177748, encodeId=19e91e77485f, content=大公司就是不一样, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Fri Feb 24 15:26:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177742, encodeId=818e1e77423b, content=好,牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/03/02/0986bbe0ac931229732ed9c7a17e5467.jpg, createdBy=9c892011128, createdName=love0711172, createdTime=Fri Feb 24 14:50:45 CST 2017, time=2017-02-24, status=1, ipAttribution=)]
    2017-02-26 tulenzi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1489933, encodeId=ea0f148993307, content=<a href='/topic/show?id=f91c93134e' target=_blank style='color:#2F92EE;'>#IBM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9313, encryptionId=f91c93134e, topicName=IBM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0288649873, createdName=tulenzi, createdTime=Sun Feb 26 05:24:00 CST 2017, time=2017-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621480, encodeId=1744162148088, content=<a href='/topic/show?id=82519314a5' target=_blank style='color:#2F92EE;'>#IBM沃森#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9314, encryptionId=82519314a5, topicName=IBM沃森)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d0520274481, createdName=yese, createdTime=Sun Feb 26 05:24:00 CST 2017, time=2017-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177858, encodeId=6ba81e78582a, content=更多的合作与思考, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sat Feb 25 13:44:38 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177748, encodeId=19e91e77485f, content=大公司就是不一样, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Fri Feb 24 15:26:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177742, encodeId=818e1e77423b, content=好,牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/03/02/0986bbe0ac931229732ed9c7a17e5467.jpg, createdBy=9c892011128, createdName=love0711172, createdTime=Fri Feb 24 14:50:45 CST 2017, time=2017-02-24, status=1, ipAttribution=)]
    2017-02-26 yese
  3. [GetPortalCommentsPageByObjectIdResponse(id=1489933, encodeId=ea0f148993307, content=<a href='/topic/show?id=f91c93134e' target=_blank style='color:#2F92EE;'>#IBM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9313, encryptionId=f91c93134e, topicName=IBM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0288649873, createdName=tulenzi, createdTime=Sun Feb 26 05:24:00 CST 2017, time=2017-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621480, encodeId=1744162148088, content=<a href='/topic/show?id=82519314a5' target=_blank style='color:#2F92EE;'>#IBM沃森#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9314, encryptionId=82519314a5, topicName=IBM沃森)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d0520274481, createdName=yese, createdTime=Sun Feb 26 05:24:00 CST 2017, time=2017-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177858, encodeId=6ba81e78582a, content=更多的合作与思考, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sat Feb 25 13:44:38 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177748, encodeId=19e91e77485f, content=大公司就是不一样, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Fri Feb 24 15:26:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177742, encodeId=818e1e77423b, content=好,牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/03/02/0986bbe0ac931229732ed9c7a17e5467.jpg, createdBy=9c892011128, createdName=love0711172, createdTime=Fri Feb 24 14:50:45 CST 2017, time=2017-02-24, status=1, ipAttribution=)]
    2017-02-25 lyh994

    更多的合作与思考

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1489933, encodeId=ea0f148993307, content=<a href='/topic/show?id=f91c93134e' target=_blank style='color:#2F92EE;'>#IBM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9313, encryptionId=f91c93134e, topicName=IBM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0288649873, createdName=tulenzi, createdTime=Sun Feb 26 05:24:00 CST 2017, time=2017-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621480, encodeId=1744162148088, content=<a href='/topic/show?id=82519314a5' target=_blank style='color:#2F92EE;'>#IBM沃森#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9314, encryptionId=82519314a5, topicName=IBM沃森)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d0520274481, createdName=yese, createdTime=Sun Feb 26 05:24:00 CST 2017, time=2017-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177858, encodeId=6ba81e78582a, content=更多的合作与思考, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sat Feb 25 13:44:38 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177748, encodeId=19e91e77485f, content=大公司就是不一样, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Fri Feb 24 15:26:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177742, encodeId=818e1e77423b, content=好,牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/03/02/0986bbe0ac931229732ed9c7a17e5467.jpg, createdBy=9c892011128, createdName=love0711172, createdTime=Fri Feb 24 14:50:45 CST 2017, time=2017-02-24, status=1, ipAttribution=)]
    2017-02-24 明月清辉

    大公司就是不一样

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1489933, encodeId=ea0f148993307, content=<a href='/topic/show?id=f91c93134e' target=_blank style='color:#2F92EE;'>#IBM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9313, encryptionId=f91c93134e, topicName=IBM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0288649873, createdName=tulenzi, createdTime=Sun Feb 26 05:24:00 CST 2017, time=2017-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621480, encodeId=1744162148088, content=<a href='/topic/show?id=82519314a5' target=_blank style='color:#2F92EE;'>#IBM沃森#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9314, encryptionId=82519314a5, topicName=IBM沃森)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d0520274481, createdName=yese, createdTime=Sun Feb 26 05:24:00 CST 2017, time=2017-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177858, encodeId=6ba81e78582a, content=更多的合作与思考, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sat Feb 25 13:44:38 CST 2017, time=2017-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177748, encodeId=19e91e77485f, content=大公司就是不一样, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Fri Feb 24 15:26:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177742, encodeId=818e1e77423b, content=好,牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/03/02/0986bbe0ac931229732ed9c7a17e5467.jpg, createdBy=9c892011128, createdName=love0711172, createdTime=Fri Feb 24 14:50:45 CST 2017, time=2017-02-24, status=1, ipAttribution=)]
    2017-02-24 love0711172

    好,牛

    0

相关资讯

超支严重却未达成目标,IBM沃森或面临与世界**癌症研究机构解约

一向风光的AI界明星IBM 沃森,近几日似乎有点烦。让我们先回到几年前。2013年10月,IBM宣布德克萨斯大学癌症中心MD Anderson正在使用IBM 沃森认知计算系统共同消灭癌症。即便在沃森陷入挫折时,MD Anderson也力挺这位“治癌新星”。可惜好景不长,日前MD Anderson宣布该项目暂停,并证实从去年年底开始,癌症中心已积极要求其他供应商投标,在未来工作中取代IBM 沃森。“

IBM沃森大力拓展医疗领域,6个新合作项目亮相

自上个月宣布推出“沃森健康部门”(Watson Health)以来,IBM一直忙个不停,陆续宣布了一系列关于其认知计算软件(沃森)在医疗保健市场的合作和部署项目。   其中大部分项目是在IBM近期于纽约召开的“沃森世界”研讨会(World of Watson)上宣布的,其中包括以下6项合作:     1. IBM沃森与梅奥诊所(Mayo Clinic

Baidu
map
Baidu
map
Baidu
map